TY - JOUR
T1 - Copy-Number Variation Contributes to the Mutational Load of Bardet-Biedl Syndrome
AU - Lindstrand, Anna
AU - Frangakis, Stephan
AU - Carvalho, Claudia M.B.
AU - Richardson, Ellen B.
AU - McFadden, Kelsey A.
AU - Willer, Jason R.
AU - Pehlivan, Davut
AU - Liu, Pengfei
AU - Pediaditakis, Igor L.
AU - Sabo, Aniko
AU - Lewis, Richard Alan
AU - Banin, Eyal
AU - Lupski, James R.
AU - Davis, Erica Ellen
AU - Katsanis, Elias Nicholas
N1 - Funding Information:
We thank the individuals with BBS and their families for their continued participation in our studies. We also thank Richard Gibbs and Donna Muzny for assistance with sequence analysis and advice, Christelle Golzio for assistance in designing and developing CRISPR protocols, and Julien Philippe for assistance with the analysis of qPCR data. This work was funded by NIH grants DK075972, HD042601, and DK096415 (N.K.), DK072301 and DK096493 (N.K. and E.E.D.), EY021872 (E.E.D.), and NS058529 and HG006542 (J.R.L.); the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) through the Young Investigator fellowship (Science without Borders Program) grant 402520/2012-2 to C.M.B.C.; funding from EU 7 th FP under GA nr. 241955, project SYSCILIA to N.K.; and by the Swedish Research Council grants 2010-978 and 2012-1526 (A.L.). R.A.L. is a Senior Scientific Investigator of Research to Prevent Blindness, whose unrestricted funds supported parts of these investigations. N.K. is a distinguished Jean and George Brumley Professor. J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, has stock options in Lasergen, Inc., is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting, and is on the Scientific Advisory Board of Baylor Genetics. N.K. is a paid consultant for and holds significant stock of Rescindo Therapeutics, Inc.
Publisher Copyright:
© 2016 American Society of Human Genetics
PY - 2016/8/4
Y1 - 2016/8/4
N2 - Bardet-Biedl syndrome (BBS) is a defining ciliopathy, notable for extensive allelic and genetic heterogeneity, almost all of which has been identified through sequencing. Recent data have suggested that copy-number variants (CNVs) also contribute to BBS. We used a custom oligonucleotide array comparative genomic hybridization (aCGH) covering 20 genes that encode intraflagellar transport (IFT) components and 74 ciliopathy loci to screen 92 unrelated individuals with BBS, irrespective of their known mutational burden. We identified 17 individuals with exon-disruptive CNVs (18.5%), including 13 different deletions in eight BBS genes (BBS1, BBS2, ARL6/BBS3, BBS4, BBS5, BBS7, BBS9, and NPHP1) and a deletion and a duplication in other ciliopathy-associated genes (ALMS1 and NPHP4, respectively). By contrast, we found a single heterozygous exon-disruptive event in a BBS-associated gene (BBS9) in 229 control subjects. Superimposing these data with resequencing revealed CNVs to (1) be sufficient to cause disease, (2) Mendelize heterozygous deleterious alleles, and (3) contribute oligogenic alleles by combining point mutations and exonic CNVs in multiple genes. Finally, we report a deletion and a splice site mutation in IFT74, inherited under a recessive paradigm, defining a candidate BBS locus. Our data suggest that CNVs contribute pathogenic alleles to a substantial fraction of BBS-affected individuals and highlight how either deletions or point mutations in discrete splice isoforms can induce hypomorphic mutations in genes otherwise intolerant to deleterious variation. Our data also suggest that CNV analyses and resequencing studies unbiased for previous mutational burden is necessary to delineate the complexity of disease architecture.
AB - Bardet-Biedl syndrome (BBS) is a defining ciliopathy, notable for extensive allelic and genetic heterogeneity, almost all of which has been identified through sequencing. Recent data have suggested that copy-number variants (CNVs) also contribute to BBS. We used a custom oligonucleotide array comparative genomic hybridization (aCGH) covering 20 genes that encode intraflagellar transport (IFT) components and 74 ciliopathy loci to screen 92 unrelated individuals with BBS, irrespective of their known mutational burden. We identified 17 individuals with exon-disruptive CNVs (18.5%), including 13 different deletions in eight BBS genes (BBS1, BBS2, ARL6/BBS3, BBS4, BBS5, BBS7, BBS9, and NPHP1) and a deletion and a duplication in other ciliopathy-associated genes (ALMS1 and NPHP4, respectively). By contrast, we found a single heterozygous exon-disruptive event in a BBS-associated gene (BBS9) in 229 control subjects. Superimposing these data with resequencing revealed CNVs to (1) be sufficient to cause disease, (2) Mendelize heterozygous deleterious alleles, and (3) contribute oligogenic alleles by combining point mutations and exonic CNVs in multiple genes. Finally, we report a deletion and a splice site mutation in IFT74, inherited under a recessive paradigm, defining a candidate BBS locus. Our data suggest that CNVs contribute pathogenic alleles to a substantial fraction of BBS-affected individuals and highlight how either deletions or point mutations in discrete splice isoforms can induce hypomorphic mutations in genes otherwise intolerant to deleterious variation. Our data also suggest that CNV analyses and resequencing studies unbiased for previous mutational burden is necessary to delineate the complexity of disease architecture.
KW - ciliopathy
KW - mechanism of rearrangements
KW - oligogenic disease
KW - zebrafish model
UR - http://www.scopus.com/inward/record.url?scp=84994184242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994184242&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2015.04.023
DO - 10.1016/j.ajhg.2015.04.023
M3 - Article
C2 - 27486776
AN - SCOPUS:84994184242
SN - 0002-9297
VL - 99
SP - 318
EP - 336
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 2
ER -